Drug Profile
Research programme: beta lactamase inhibitors - Merck
Alternative Names: BLIs - MerckLatest Information Update: 27 Mar 2023
Price :
$50
*
At a glance
- Originator Cubist Pharmaceuticals
- Developer Merck & Co
- Class Antibacterials; Small molecules
- Mechanism of Action Beta lactamase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gram-negative infections
Most Recent Events
- 27 Mar 2023 Discontinued - Preclinical for Gram-negative infections in USA (unspecified route)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Gram-negative-infections in USA
- 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co